Genprex, Inc., a clinical-stage gene therapy biotechnology company, develops immunogene therapy products for treating cancer. Its lead drug candidate is
Oncoprex, which is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also conducting preclinical research for developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas. The company trades on NASDAQ exchange. The company headquarter is located in Austin, TX. The company was established in the 2009.
| Ticker | GNPX |
| Long Name | Genprex, Inc. |
| Short Name | Genprex |